Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | OGFRL1 | Q5TC84 | 6/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9205301 | 0.84 | EGLN1 (0.40) | ALOX15SLC6A9POLB | |
| SCHEMBL9266166 | 0.82 | SLC6A9 (0.34) | SLC6A9POLB | |
| SCHEMBL1394889 | 0.82 | SLC6A9 (0.42) | SLC6A9POLB | |
| SCHEMBL7869921 | 0.81 | EGLN1 (0.39) | NPC1ALOX15SLC6A9POLB | |
| SCHEMBL16021612 | 0.80 | SLC6A9 (0.44) | SLC6A9 | |
| SCHEMBL7871400 | 0.80 | ALDH1A1 (0.40) | NPC1ALOX15POLB | |
| SCHEMBL9024977 | 0.79 | SIGMAR1 (0.35) | SLC6A9POLBDRD2DRD4 | |
| SCHEMBL20624199 | 0.78 | EGLN1 (0.36) | SLC6A9POLB | |
| SCHEMBL23975536 | 0.78 | SLC6A9 (0.36) | SLC6A9 | |
| SCHEMBL24201117 | 0.78 | SLC6A9 (0.40) | SLC6A9CHRM1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041776-A1 | POLYMER CONTRAST AGENT | KOWA COMPANY, LTD. (JP) | 2026-02-12 | — | — | US | disclosed |
| EP-4570837-A1 | POLYMER CONTRAST AGENT | KOWA COMPANY, LTD. (JP) | 2025-06-18 | — | — | EP | disclosed |
| CN-119677788-A | Polymer contrast medium | 兴和株式会社 | 2025-03-21 | — | — | CN | disclosed |
| WO-2024034686-A1 | POLYMER CONTRAST AGENT | 興和株式会社 | 2024-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041776-A1 | POLYMER CONTRAST AGENT | RXFP3, HAX1, MSR1 | NPC1 1418/4885LMNA 1424/4885ALOX15 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.